# A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation

> **NCT03950843** · PHASE3 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 162 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** CKD-825
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03950843
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-23
- **Primary completion:** 2021-09
- **Final completion:** 2021-12
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950843, "A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03950843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*